Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Nazartinib · EGF-816

Small molecule · Inhibitor of epidermal growth factor receptor (mutant forms, including T790M) (EGFR) · developed by Novartis Pharmaceuticals

Phase 1 Most advanced trial
NVS Developer

What is Nazartinib?

Nazartinib is an orally available, irreversible, third-generation EGFR inhibitor that covalently binds mutant forms of EGFR, including the T790M resistance mutation, and inhibits their signaling. It is being studied in EGFR-mutant non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
EGF-816
Drug type
Small molecule
Targets
epidermal growth factor receptor (mutant forms, including T790M) (EGFR)
Mechanism
Inhibitor of epidermal growth factor receptor (mutant forms, including T790M) (EGFR)
Pathways
EGFR signaling, tumor cell proliferation, tumor vascularization
Therapy area
Oncology
Developer
Novartis Pharmaceuticals (NVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
KE7K32EME8

Conditions studied

EGFR-mutant Non-small Cell Lung Cancer

Other drugs acting on EGFR

More from Novartis Pharmaceuticals

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Nazartinib

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.